8-K: Revelation Biosciences Secures $4 Million in Public Offering to Advance Clinical Programs

Revelation Biosciences, Inc. has successfully closed a public offering raising approximately $4 million in gross proceeds to fund its ongoing clinical studies and product development.

Summary

• Revelation Biosciences, Inc. completed a public offering of 3,640,000 shares of its common stock (or common stock equivalents) and warrants to purchase up to 14,560,000 shares of common stock.
• The combined offering price was $1.10 per share of common stock and associated warrant, resulting in gross proceeds of approximately $4.0 million.
• The offering included 2,965,000 pre-funded warrants with an exercise price of $0.0001 per share, all of which were exercised subsequent to the closing.
• Additionally, 14,560,000 Class H Common Stock Warrants were issued with an exercise price of $1.10 per share, exercisable upon stockholder approval, and expiring five years from the initial exercise date.
• Roth Capital Partners, LLC acted as the sole placement agent for the offering.
• The company paid the placement agent a cash fee of 8% of the aggregate gross proceeds, plus reimbursement of $125,000 for certain expenses and legal fees.
• The company, its executive officers, and directors have agreed to a 90-day lock-up period, restricting the sale or disposal of company securities.

Sentiment

Score: 6

Explanation: The successful completion of the capital raise provides necessary funding for Revelation Biosciences' critical clinical programs, which is a positive for a clinical-stage company. However, the highly dilutive nature of the offering, particularly the large number of warrants and their contingent exercise, indicates a challenging capital market environment and could exert downward pressure on the stock price, balancing the positive of securing funds.

Positives

• Successfully raised approximately $4.0 million in gross proceeds, providing crucial funding for ongoing and future clinical development programs.
• All pre-funded warrants were exercised immediately after closing, indicating prompt capital infusion from that component of the offering.
• Proceeds are earmarked for key development milestones, including the completion of a Phase 1b clinical study, manufacture of clinical drug supply, and additional preclinical work for multiple indications.

Negatives

• The offering involves significant potential dilution from the issuance of 3,640,000 shares/equivalents and up to 14,560,000 warrants.
• The placement agent received a substantial fee of 8% of gross proceeds plus $125,000 in expenses, representing a notable portion of the capital raised.
• The exercise of Class H Common Stock Warrants is contingent upon stockholder approval, introducing a potential delay or uncertainty for future capital realization from these warrants.
• The exercise price of Class H Warrants ($1.10) is subject to reduction in the event of certain future dilutive issuances or a reverse stock split, which could lead to further dilution for existing shareholders.

Risks

• The company faces competition in the life sciences industry.
• Ability to grow and manage growth profitably and retain key employees is a risk.
• The company may be adversely affected by other economic, business, and/or competitive factors.
• Risks relate to the successful development of Revelation's product candidates.
• There is a risk that clinical studies may not fully enroll or enrollment will take longer than expected.
• Potential for adverse safety events and/or unexpected concerns arising from data or analysis from clinical studies.
• Changes in applicable laws or regulations could impact operations.
• Uncertainty regarding the timing, costs, conduct, and outcome of clinical studies.
• The anticipated treatment of future clinical data by regulatory authorities (FDA, EMA) and whether such data will be sufficient for approval is a risk.
• Success of future development activities for product candidates is not guaranteed.
• Potential indications for which product candidates may be developed are subject to change.
• Ability to maintain the listing of its securities on NASDAQ is a concern.
• The expected duration over which Revelation's balances will fund its operations is uncertain.

Future Outlook

The company intends to use the net proceeds from this offering to further the development of its product candidates, specifically for the completion of its ongoing Phase 1b clinical study, the manufacture of clinical drug supply, additional preclinical work for multiple indications, and to continue developing other products and therapies. Any remaining amounts will be used for working capital and general corporate purposes.

Management Comments

• Chester S. Zygmont, III, Chief Financial Officer, is listed as a company contact for investor relations and signed the 8-K filing and associated agreements.

Industry Context

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, utilizing its proprietary Gemini formulation. This public offering provides essential capital for the company to advance its pipeline, which includes programs targeting post-surgical infection, acute kidney injury, and chronic kidney disease. Such capital raises are typical for clinical-stage biotech firms to fund costly research and development, particularly clinical trials, as they progress towards potential commercialization.

Comparison to Industry Standards

• The offering structure, including a significant number of warrants (approximately 400% coverage for Class H warrants) relative to the shares/equivalents, is indicative of a highly dilutive financing, often seen in small-cap clinical-stage biotech companies seeking to raise capital in challenging market conditions or with limited alternative financing options.
• The 8% cash fee and $125,000 expense reimbursement paid to the placement agent are within the customary range for 'reasonable best efforts' public offerings for companies of this size and stage, reflecting the costs associated with accessing public capital markets.
• The 90-day lock-up period for company insiders (executive officers and directors) is a standard practice in public offerings, designed to signal management's commitment and stability to new investors.
• The requirement for stockholder approval for the exercise of the Class H Warrants is a common compliance measure for Nasdaq-listed companies when an issuance could exceed 20% of outstanding shares, aiming to protect existing shareholder interests from excessive dilution without their consent.

Corporate Governance

Related Party Transactions

• Executive officers and directors are subject to a 90-day lock-up agreement on their securities, which is a standard practice in public offerings.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience significant dilution from the issuance of new shares and the potential future exercise of 14,560,000 Class H warrants.
• **New Investors**: New investors gain exposure to the company's clinical pipeline and potential upside, but also assume the risks associated with clinical development and future dilution.
• **Employees**: The capital raise provides funding for ongoing research and development, potentially securing jobs and advancing product candidates, which is positive for employee morale and stability.

Next Steps

• Complete the ongoing Phase 1b clinical study.
• Manufacture clinical drug supply for product candidates.
• Conduct additional preclinical work for multiple indications.
• Continue to develop other products and therapies.
• Hold a special meeting of stockholders on or prior to 60 days after the Closing Date to obtain Stockholder Approval for the issuance of shares upon exercise of the Class H Common Stock Warrants.
• If Stockholder Approval is not obtained at the first meeting, call subsequent meetings every 60 days until approval is secured or warrants are no longer outstanding.

Key Dates

Recommendation

Keywords

Revelation Biosciences, REVB, Public Offering, Warrants, Common Stock, Pre-Funded Warrants, Class H Warrants, Capital Raise, Clinical Stage, Life Sciences, Biotechnology, Inflammation, Gemini, Post-Surgical Infection, Acute Kidney Injury, Chronic Kidney Disease, NASDAQ, SEC Filing, 8-K